Aperture Therapeutics is advancing APRTX-003, an RNA-based antisense therapy targeting MMP9, as a potential ALS treatment.

Pancreatic ductal adenocarcinoma (PDAC) is the most lethal form of pancreas cancer. It's also the most common form of the ...

Bayer and Soufflé Therapeutics™, an innovative biotech company that discovers and develops cell-selective genetic therapies, ...

Veteran immunologist and former Pfizer R&D leader joins Circurna to advance its circular RNA therapeutic platform ...

Cow’s milk contains nanoparticles that can be used to deliver disease-modifying RNA therapy orally, according to a new study. With RNA-based drugs currently only administrable by injection, the ...

Ascidian Therapeutics ("Ascidian"), a biotechnology company seeking to treat human diseases by rewriting RNA, and Forge ...

RNA therapies are emerging as a promising treatment for cancer, but some types of the disease don’t respond well to it. Now, scientists at Tel Aviv University have demonstrated a way to use RNA drugs ...

Nearly 1.3 billion adults around the world have clinically high blood pressure, many of whom may be unaware that they are living with this condition. Nearly 1.3 billion adults around the world have ...

A developer of RNA editing therapies whose lead program targets Alpha-1 antitrypsin deficiency (AATD) said today it has closed an oversubscribed $60 million Series A financing, with plans that include ...

An experimental RNA therapy from Avidity Biosciences has early clinical trial results showing it reduced by half the expression of a gene at the root of a rare, inherited form of muscular dystrophy ...

The ability to control the expression of therapeutic genes within a “therapeutic window” is crucial to ensure the development of safe and effective gene therapies, but to date, there has been no ...

Lipid-based nanoparticles are a popular research area as a non-viral platform for delivering RNA molecules and include liposomes, lipoplexes, lipid nanoparticles and solid lipid nanoparticles. Using ...